Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
05 janv. 2024 08h30 HE
|
Journey Medical Corporation
If approved, DFD-29 has potential to be best-in-class and the only oral medication to address both inflammatory lesions and erythema (redness) from rosacea NDA submission supported by positive Phase...
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
04 janv. 2024 08h30 HE
|
Avenue Therapeutics
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of...
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
02 janv. 2024 08h35 HE
|
Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
02 janv. 2024 08h30 HE
|
Daxor Corporation
The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global...
Theratechnologies soumet une demande supplémentaire de licence de produit biologique (sBLA) à la FDA pour l’administration intramusculaire (IM) de Trogarzoᴹᴰ
02 janv. 2024 07h30 HE
|
Theratechnologies
L’administration intramusculaire de la dose de maintien de TrogarzoMD vise à offrir des traitements pratiques qui ne sont pas administrés par voie orale aux adultes vivant avec le VIH qui ont déjà...
Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
02 janv. 2024 07h30 HE
|
Theratechnologies
Trogarzo® IM maintenance dosing aims to further enhance the convenience of non-oral therapy for heavily treatment-experienced adults with HIV Submission comes on the heels of the recent FDA approval...
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
02 janv. 2024 07h05 HE
|
Virios Therapeutics
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to...
BCLI FINAL DEADLINE TOMORROW: ROSEN, A TOP RANKED LAW FIRM, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm – BCLI
01 janv. 2024 13h55 HE
|
The Rosen Law Firm PA
NEW YORK, Jan. 01, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between...
BCLI DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action Commenced by the Firm – BCLI
28 déc. 2023 17h03 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between...
MIST NEWS: ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
28 déc. 2023 16h01 HE
|
The Rosen Law Firm PA
NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone...